$GLUE
Monte Rosa Therapeutics, Inc.

2024 Q1 Form 10-K Financial Statement

#000095017024031150 Filed on March 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $1.064M $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.985M $7.728M $39.94M
YoY Change 19.74% -43.38% 13.71%
% of Gross Profit
Research & Development $27.03M $27.14M $111.3M
YoY Change 1.01% 9.12% 30.81%
% of Gross Profit
Depreciation & Amortization $1.900M $1.846M $6.200M
YoY Change 58.33% 72.52% 67.57%
% of Gross Profit
Operating Expenses $36.01M $34.86M $143.3M
YoY Change 5.11% 7.31% 27.52%
Operating Profit -$34.95M -$143.3M
YoY Change 2.01% 27.52%
Interest Expense $2.442M $1.589M $9.334M
YoY Change 0.21% -6.91% 147.98%
% of Operating Profit
Other Income/Expense, Net $3.062M $8.297M
YoY Change 37.87% 113.67%
Pretax Income -$31.89M -$33.27M -$135.0M
YoY Change -0.48% 8.1% 683.51%
Income Tax $100.0K -$22.00K $338.0K
% Of Pretax Income
Net Earnings -$31.97M -$33.25M -$135.4M
YoY Change -0.22% 8.02% 24.75%
Net Earnings / Revenue -3004.51%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.53 -$0.58 -$2.63
COMMON SHARES
Basic Shares Outstanding 50.15M 50.08M 51.40M
Diluted Shares Outstanding 60.16M 51.40M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $192.9M $232.4M $232.4M
YoY Change -16.76% -11.57% -11.57%
Cash & Equivalents $99.75M $128.1M $128.1M
Short-Term Investments $93.14M $104.3M $104.3M
Other Short-Term Assets $5.543M $3.294M $3.294M
YoY Change -16.67% -39.05% -39.05%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $199.0M $236.2M $236.2M
YoY Change -17.26% -14.38% -14.38%
LONG-TERM ASSETS
Property, Plant & Equipment $34.04M $33.80M $62.61M
YoY Change 2.31% 24.85% 1.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $389.0K $352.0K $4.932M
YoY Change 10.83% 26.62% 7.31%
Total Long-Term Assets $67.71M $67.54M $67.54M
YoY Change -1.11% 1.56% 1.56%
TOTAL ASSETS
Total Short-Term Assets $199.0M $236.2M $236.2M
Total Long-Term Assets $67.71M $67.54M $67.54M
Total Assets $266.7M $303.8M $303.8M
YoY Change -13.68% -11.28% -11.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.828M $11.15M $11.15M
YoY Change -7.5% 41.85% 41.85%
Accrued Expenses $14.06M $17.76M $17.76M
YoY Change 7.04% 0.31% 0.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $41.29M $46.59M $46.59M
YoY Change 101.28% 82.22% 82.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $72.93M $77.91M $77.91M
YoY Change 62.85% 71.59% 71.59%
Total Long-Term Liabilities $72.93M $77.91M $77.91M
YoY Change 62.85% 71.59% 71.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $41.29M $46.59M $46.59M
Total Long-Term Liabilities $72.93M $77.91M $77.91M
Total Liabilities $114.2M $124.5M $124.5M
YoY Change 74.92% 75.42% 75.42%
SHAREHOLDERS EQUITY
Retained Earnings -$397.9M -$365.9M
YoY Change 51.52% 58.74%
Common Stock $553.1M $547.9M
YoY Change 8.94% 8.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $152.5M $179.3M $179.3M
YoY Change
Total Liabilities & Shareholders Equity $266.7M $303.8M $303.8M
YoY Change -13.68% -11.28% -11.28%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$31.97M -$33.25M -$135.4M
YoY Change -0.22% 8.02% 24.75%
Depreciation, Depletion And Amortization $1.900M $1.846M $6.200M
YoY Change 58.33% 72.52% 67.57%
Cash From Operating Activities -$38.17M $29.63M -$43.80M
YoY Change 63.06% -223.68% -52.63%
INVESTING ACTIVITIES
Capital Expenditures $1.384M $1.689M $19.04M
YoY Change -84.93% -76.77% 47.48%
Acquisitions
YoY Change
Other Investing Activities $11.24M $15.99M $107.8M
YoY Change -61.92% -134.25% -152.27%
Cash From Investing Activities $9.853M $14.30M $88.80M
YoY Change -51.53% -126.51% -140.51%
FINANCING ACTIVITIES
Cash Dividend Paid $0.00 $0.00
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 246.0K 25.17M 27.49M
YoY Change 1266.67% 23.19% 34.33%
NET CHANGE
Cash From Operating Activities -38.17M 29.63M -43.80M
Cash From Investing Activities 9.853M 14.30M 88.80M
Cash From Financing Activities 246.0K 25.17M 27.49M
Net Change In Cash -28.07M 69.10M 72.49M
YoY Change 816.59% -220.25% -124.89%
FREE CASH FLOW
Cash From Operating Activities -$38.17M $29.63M -$43.80M
Capital Expenditures $1.384M $1.689M $19.04M
Free Cash Flow -$39.55M $27.95M -$62.84M
YoY Change 21.36% -189.48% -40.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001826457
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-40522
CY2023 dei Entity Registrant Name
EntityRegistrantName
Monte Rosa Therapeutics, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3766197
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
321 Harrison Avenue
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 900
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02118
CY2023 dei City Area Code
CityAreaCode
617
CY2023 dei Local Phone Number
LocalPhoneNumber
949-2643
CY2023 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2023 dei Trading Symbol
TradingSymbol
GLUE
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
234300000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
50154073
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Name
AuditorName
Deloitte & Touche LLP
CY2023 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2023 dei Auditor Firm
AuditorFirmId
34
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
128101000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54912000
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
104312000
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
207914000
CY2023Q4 us-gaap Other Receivables
OtherReceivables
505000
CY2022Q4 us-gaap Other Receivables
OtherReceivables
7656000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3294000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4444000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
960000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
236212000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
275886000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33803000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27075000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28808000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
34832000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4580000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4318000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
352000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
278000
CY2023Q4 us-gaap Assets
Assets
303755000
CY2022Q4 us-gaap Assets
Assets
342389000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11152000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7862000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
14600000
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
14580000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
17678000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3162000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3127000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
46592000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25569000
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
32323000
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
0
CY2023Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
2713000
CY2022Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
1533000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
42877000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
43874000
CY2023Q4 us-gaap Liabilities
Liabilities
124505000
CY2022Q4 us-gaap Liabilities
Liabilities
70976000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-108501000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
338000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50154929
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50140233
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49445802
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49323531
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
547857000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
503696000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2724000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1752000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-365888000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-230536000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
179250000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
271413000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
303755000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
342389000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
111272000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
85061000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32039000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27323000
CY2023 us-gaap Operating Expenses
OperatingExpenses
143311000
CY2022 us-gaap Operating Expenses
OperatingExpenses
112384000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-143311000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-112384000
CY2023 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
9334000
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3764000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-930000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
10000
CY2023 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
24000
CY2022 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
109000
CY2023 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-131000
CY2022 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
0
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8297000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3883000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-135014000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-135352000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-108501000
CY2023 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.63
CY2023 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.63
CY2022 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.3
CY2022 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.3
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51396961
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51396961
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47227370
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47227370
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-135352000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-108501000
CY2023 glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
-1369000
CY2022 glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
718000
CY2023 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
-397000
CY2022 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
449000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-136324000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-108232000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
347515000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
439000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11664000
CY2022 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
718000
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
984000
CY2022 glue Issuance Of Common Stock Net Of Issuance Costs
IssuanceOfCommonStockNetOfIssuanceCosts
19691000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
449000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
336000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-108501000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
271413000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2030000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16669000
CY2023 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-1369000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
397000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
578000
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
116000
CY2023 glue Issuance Of Pre Funded Warrant Net Of Issuance Costs
IssuanceOfPreFundedWarrantNetOfIssuanceCosts
24884000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-135352000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
179250000
CY2023 us-gaap Profit Loss
ProfitLoss
-135352000
CY2022 us-gaap Profit Loss
ProfitLoss
-108501000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
16669000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
11664000
CY2023 us-gaap Depreciation
Depreciation
6222000
CY2022 us-gaap Depreciation
Depreciation
3745000
CY2023 glue Noncash Lease Expense
NoncashLeaseExpense
0
CY2022 glue Noncash Lease Expense
NoncashLeaseExpense
4814000
CY2023 glue Accretion Of Discounts Premiums On Marketable Securities Net
AccretionOfDiscountsPremiumsOnMarketableSecuritiesNet
-3914000
CY2022 glue Accretion Of Discounts Premiums On Marketable Securities Net
AccretionOfDiscountsPremiumsOnMarketableSecuritiesNet
-1945000
CY2023 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-131000
CY2022 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
24000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
109000
CY2023 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1897000
CY2022 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
187000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1077000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2127000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5758000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-744000
CY2023 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3557000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1031000
CY2023 us-gaap Defined Benefit Plan Other Changes
DefinedBenefitPlanOtherChanges
188000
CY2022 us-gaap Defined Benefit Plan Other Changes
DefinedBenefitPlanOtherChanges
-74000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
10365000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-181000
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
50000000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43802000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-92466000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19041000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12911000
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
62000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
109000
CY2023 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
103151000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
384417000
CY2023 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
45631000
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2023 glue Proceedsfrommaturityofmarketablesecurities
Proceedsfrommaturityofmarketablesecurities
165300000
CY2022 glue Proceedsfrommaturityofmarketablesecurities
Proceedsfrommaturityofmarketablesecurities
178000000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
88801000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-219219000
CY2023 glue Net Of Underwriting Discount On Issuance Of Common Stock
NetOfUnderwritingDiscountOnIssuanceOfCommonStock
620000
CY2022 glue Net Of Underwriting Discount On Issuance Of Common Stock
NetOfUnderwritingDiscountOnIssuanceOfCommonStock
620000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20055000
CY2023 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
25000000
CY2022 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2030000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
439000
CY2023 us-gaap Proceeds From Issuance Of Common Stock Dividend Reinvestment Plan
ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan
578000
CY2022 us-gaap Proceeds From Issuance Of Common Stock Dividend Reinvestment Plan
ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan
336000
CY2023 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0
CY2022 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
364000
CY2023 glue Payment To Pre Funded Warrant Issuance Costs
PaymentToPreFundedWarrantIssuanceCosts
116000
CY2022 glue Payment To Pre Funded Warrant Issuance Costs
PaymentToPreFundedWarrantIssuanceCosts
0
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27492000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20466000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
72491000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-291219000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60190000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
351409000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
132681000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60190000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
128101000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54912000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
4580000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
5278000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
132681000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60190000
CY2023 glue Reduction Of Right Of Use Assets For Lease Incentives Receivable
ReductionOfRightOfUseAssetsForLeaseIncentivesReceivable
5253000
CY2022 glue Reduction Of Right Of Use Assets For Lease Incentives Receivable
ReductionOfRightOfUseAssetsForLeaseIncentivesReceivable
7469000
CY2023 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
237000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6240000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-365900000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-135400000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-108500000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
232400000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, including those related to accrued research and development expenses, other long-lived assets, pension benefit obligation, stock-based compensation and the valuation of deferred tax assets. The Company bases its estimates using historical experience, Company forecasts and future plans, current economic conditions, and information from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources and adjusts those estimates and assumptions when facts and circumstances dictate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1000000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
300000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
236420000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
263867000
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
104365000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
68000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
104312000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
208363000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
29000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
478000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
207914000
CY2023 glue Number Of Marketable Securities Held
NumberOfMarketableSecuritiesHeld
28
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
72900000
CY2022 glue Number Of Marketable Securities Held
NumberOfMarketableSecuritiesHeld
40
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
164900000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
46047000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33326000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12244000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6251000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33803000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27075000
CY2023 us-gaap Depreciation
Depreciation
6200000
CY2022 us-gaap Depreciation
Depreciation
3700000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7593000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5624000
CY2023Q4 glue Accrued Research And Development
AccruedResearchAndDevelopment
5336000
CY2022Q4 glue Accrued Research And Development
AccruedResearchAndDevelopment
3936000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1671000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5020000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
14600000
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
14580000
CY2023Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
CY2023 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
13000000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
7141000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
6924000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
2317000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
1898000
CY2023 us-gaap Lease Cost
LeaseCost
9458000
CY2022 us-gaap Lease Cost
LeaseCost
8822000
CY2023 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y7M6D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y8M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.098
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.099
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1871000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
48488000
CY2023 glue Cash Paid For Amount Included In Measurement Of Lease Liabilities
CashPaidForAmountIncludedInMeasurementOfLeaseLiabilities
2995000
CY2022 glue Cash Paid For Amount Included In Measurement Of Lease Liabilities
CashPaidForAmountIncludedInMeasurementOfLeaseLiabilities
1654000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2500000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3300000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50154929
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50140233
CY2023Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2023 us-gaap Payments Of Dividends
PaymentsOfDividends
0
CY2023 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7436339
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.14
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12440000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3388425
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.36
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
561905
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.61
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
867929
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.24
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9394930
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.78
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4741000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
9394930
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
8.78
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
4741000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3922618
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.93
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y3M18D
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3442000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.4
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.44
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M26D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8272
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7882
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0395
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0202
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16669000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11664000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-19543000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-17232000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-115471000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-91269000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-135014000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-108501000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.062
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.062
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.068
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.067
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
-0.007
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
-0.007
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.195
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.198
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
41888000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
26136000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2245000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1715000
CY2023Q4 glue Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
3679000
CY2022Q4 glue Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
1151000
CY2023Q4 glue Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
12403000
CY2022Q4 glue Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
13173000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
6283000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
4022000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
147000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
149000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
66645000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
46346000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
54465000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
33084000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
12180000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
13262000
CY2023Q4 glue Deferred Tax Right Of Use Assets
DeferredTaxRightOfUseAssets
-7573000
CY2022Q4 glue Deferred Tax Right Of Use Assets
DeferredTaxRightOfUseAssets
-11766000
CY2023Q4 us-gaap Defined Benefit Pension Plan Current And Noncurrent Liabilities
DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities
332000
CY2022Q4 us-gaap Defined Benefit Pension Plan Current And Noncurrent Liabilities
DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities
375000
CY2023Q4 glue Deferred Tax Assets Prepaid Insurance
DeferredTaxAssetsPrepaidInsurance
0
CY2022Q4 glue Deferred Tax Assets Prepaid Insurance
DeferredTaxAssetsPrepaidInsurance
-252000
CY2023Q4 glue Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
4275000
CY2022Q4 glue Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
869000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
12180000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
13262000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
21400000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2235000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
2369000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
2235000
CY2023 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
129000
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4475000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2235000
CY2022Q4 us-gaap Defined Benefit Plan Benefit Obligation
DefinedBenefitPlanBenefitObligation
6851000
CY2021Q4 us-gaap Defined Benefit Plan Benefit Obligation
DefinedBenefitPlanBenefitObligation
5975000
CY2023 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
774000
CY2022 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
549000
CY2023 glue Defined Benefit Plan Contributions Paid By Employees
DefinedBenefitPlanContributionsPaidByEmployees
657000
CY2022 glue Defined Benefit Plan Contributions Paid By Employees
DefinedBenefitPlanContributionsPaidByEmployees
299000
CY2023 us-gaap Interest Expense Other
InterestExpenseOther
198000
CY2022 us-gaap Interest Expense Other
InterestExpenseOther
19000
CY2023 us-gaap Defined Benefit Plan Benefit Obligation Contributions By Plan Participant
DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
2752000
CY2022 us-gaap Defined Benefit Plan Benefit Obligation Contributions By Plan Participant
DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
1302000
CY2023 us-gaap Defined Benefit Plan Benefit Obligation Benefits Paid
DefinedBenefitPlanBenefitObligationBenefitsPaid
594000
CY2022 us-gaap Defined Benefit Plan Benefit Obligation Benefits Paid
DefinedBenefitPlanBenefitObligationBenefitsPaid
452000
CY2023 us-gaap Defined Benefit Plan Plan Amendments
DefinedBenefitPlanPlanAmendments
-1463000
CY2022 us-gaap Defined Benefit Plan Plan Amendments
DefinedBenefitPlanPlanAmendments
-67000
CY2023 us-gaap Defined Benefit Plan Actuarial Gain Loss
DefinedBenefitPlanActuarialGainLoss
2854000
CY2022 us-gaap Defined Benefit Plan Actuarial Gain Loss
DefinedBenefitPlanActuarialGainLoss
-774000
CY2023Q4 us-gaap Defined Benefit Plan Benefit Obligation
DefinedBenefitPlanBenefitObligation
12029000
CY2022Q4 us-gaap Defined Benefit Plan Benefit Obligation
DefinedBenefitPlanBenefitObligation
6851000
CY2022Q4 us-gaap Defined Benefit Plan Fair Value Of Plan Assets
DefinedBenefitPlanFairValueOfPlanAssets
5318000
CY2021Q4 us-gaap Defined Benefit Plan Fair Value Of Plan Assets
DefinedBenefitPlanFairValueOfPlanAssets
3799000
CY2023 us-gaap Defined Benefit Plan Actual Return On Plan Assets
DefinedBenefitPlanActualReturnOnPlanAssets
-96000
CY2022 us-gaap Defined Benefit Plan Actual Return On Plan Assets
DefinedBenefitPlanActualReturnOnPlanAssets
-240000
CY2023 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
1279000
CY2022 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
610000
CY2023 glue Defined Benefit Plan Assets Contributions Paid By Employees
DefinedBenefitPlanAssetsContributionsPaidByEmployees
657000
CY2022 glue Defined Benefit Plan Assets Contributions Paid By Employees
DefinedBenefitPlanAssetsContributionsPaidByEmployees
299000
CY2023 us-gaap Defined Benefit Plan Plan Assets Contributions By Plan Participant
DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
2752000
CY2022 us-gaap Defined Benefit Plan Plan Assets Contributions By Plan Participant
DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
1302000
CY2023 us-gaap Defined Benefit Plan Plan Assets Benefits Paid
DefinedBenefitPlanPlanAssetsBenefitsPaid
594000
CY2022 us-gaap Defined Benefit Plan Plan Assets Benefits Paid
DefinedBenefitPlanPlanAssetsBenefitsPaid
452000
CY2023Q4 us-gaap Defined Benefit Plan Fair Value Of Plan Assets
DefinedBenefitPlanFairValueOfPlanAssets
9316000
CY2022Q4 us-gaap Defined Benefit Plan Fair Value Of Plan Assets
DefinedBenefitPlanFairValueOfPlanAssets
5318000
CY2023Q4 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Current And Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
2713000
CY2022Q4 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Current And Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
1533000
CY2023 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
774000
CY2022 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
549000
CY2023 us-gaap Interest Expense Other
InterestExpenseOther
198000
CY2022 us-gaap Interest Expense Other
InterestExpenseOther
19000
CY2023 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
972000
CY2022 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
568000
CY2023 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
-1614000
CY2022 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
774000
CY2023 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent
-1240000
CY2022 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent
0
CY2023 us-gaap Amount Recognized In Net Periodic Benefit Cost And Other Comprehensive Income Loss Before Tax
AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
-2854000
CY2022 us-gaap Amount Recognized In Net Periodic Benefit Cost And Other Comprehensive Income Loss Before Tax
AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
774000
CY2023 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Inflation Rate
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInflationRate
0.0125
CY2022 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Inflation Rate
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInflationRate
0.0125
CY2023 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
0.015
CY2022 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
0.023
CY2023 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Interest Rate On Savings Accounts
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestRateOnSavingsAccounts
0.01
CY2022 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Interest Rate On Savings Accounts
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestRateOnSavingsAccounts
0.01
CY2023 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
0.015
CY2022 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
0.023
CY2023 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
0.0125
CY2022 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
0.0125
CY2023 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Social Security Increase
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostSocialSecurityIncrease
0.0125
CY2022 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Social Security Increase
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostSocialSecurityIncrease
0.0125
CY2023 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Pension Increase
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostPensionIncrease
0
CY2022 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Pension Increase
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostPensionIncrease
0
CY2023 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Retirement Description
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRetirementDescription
100% Male 65 Female 64
CY2022 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Retirement Description
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRetirementDescription
100% Male 65 Female 64
CY2023 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Mortality And Disability Rate Description
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostMortalityAndDisabilityRateDescription
BVG 2020 Table
CY2022 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Mortality And Disability Rate Description
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostMortalityAndDisabilityRateDescription
BVG 2020 Table
CY2023Q4 us-gaap Defined Benefit Plan Expected Future Benefit Payments Next Twelve Months
DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
1052000
CY2023Q4 us-gaap Defined Benefit Plan Expected Future Benefit Payments Year Two
DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
1075000
CY2023Q4 us-gaap Defined Benefit Plan Expected Future Benefit Payments Year Three
DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
1092000
CY2023Q4 us-gaap Defined Benefit Plan Expected Future Benefit Payments Year Four
DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
1106000
CY2023Q4 us-gaap Defined Benefit Plan Expected Future Benefit Payments Year Five
DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
1122000
CY2023Q4 us-gaap Defined Benefit Plan Expected Future Benefit Payments Five Fiscal Years Thereafter
DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
6300000
CY2023 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
1
CY2023 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.04
CY2023 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
600000
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
500000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-135352000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-108501000
CY2023 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.63
CY2023 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.63
CY2022 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.3
CY2022 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.3
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51396961
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51396961
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47227370
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47227370

Files In Submission

Name View Source Status
0000950170-24-031150-index-headers.html Edgar Link pending
0000950170-24-031150-index.html Edgar Link pending
0000950170-24-031150.txt Edgar Link pending
0000950170-24-031150-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
glue-20231231.htm Edgar Link pending
glue-20231231.xsd Edgar Link pending
glue-ex21_1.htm Edgar Link pending
glue-ex23_1.htm Edgar Link pending
glue-ex31_1.htm Edgar Link pending
glue-ex32_1.htm Edgar Link pending
glue-ex4_2.htm Edgar Link pending
glue-ex97_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
glue-20231231_htm.xml Edgar Link completed
img9313878_0.jpg Edgar Link pending
img9313878_1.jpg Edgar Link pending
img9313878_10.jpg Edgar Link pending
img9313878_11.jpg Edgar Link pending
img9313878_12.jpg Edgar Link pending
img9313878_13.jpg Edgar Link pending
img9313878_14.jpg Edgar Link pending
img9313878_15.jpg Edgar Link pending
img9313878_16.jpg Edgar Link pending
img9313878_17.jpg Edgar Link pending
img9313878_18.jpg Edgar Link pending
img9313878_19.jpg Edgar Link pending
img9313878_2.jpg Edgar Link pending
img9313878_20.jpg Edgar Link pending
img9313878_21.jpg Edgar Link pending
img9313878_22.jpg Edgar Link pending
img9313878_23.jpg Edgar Link pending
img9313878_24.jpg Edgar Link pending
img9313878_25.jpg Edgar Link pending
img9313878_26.jpg Edgar Link pending
img9313878_27.jpg Edgar Link pending
img9313878_28.jpg Edgar Link pending
img9313878_29.jpg Edgar Link pending
img9313878_3.jpg Edgar Link pending
img9313878_30.jpg Edgar Link pending
img9313878_31.jpg Edgar Link pending
img9313878_32.jpg Edgar Link pending
img9313878_33.jpg Edgar Link pending
img9313878_34.jpg Edgar Link pending
img9313878_35.jpg Edgar Link pending
img9313878_36.jpg Edgar Link pending
img9313878_37.jpg Edgar Link pending
img9313878_38.jpg Edgar Link pending
img9313878_39.jpg Edgar Link pending
img9313878_4.jpg Edgar Link pending
img9313878_40.jpg Edgar Link pending
img9313878_41.jpg Edgar Link pending
img9313878_42.jpg Edgar Link pending
img9313878_43.jpg Edgar Link pending
img9313878_44.jpg Edgar Link pending
img9313878_45.jpg Edgar Link pending
img9313878_46.jpg Edgar Link pending
img9313878_47.jpg Edgar Link pending
img9313878_48.jpg Edgar Link pending
img9313878_49.jpg Edgar Link pending
img9313878_5.jpg Edgar Link pending
img9313878_50.jpg Edgar Link pending
img9313878_51.jpg Edgar Link pending
img9313878_52.jpg Edgar Link pending
img9313878_53.jpg Edgar Link pending
img9313878_54.jpg Edgar Link pending
img9313878_55.jpg Edgar Link pending
img9313878_56.jpg Edgar Link pending
img9313878_6.jpg Edgar Link pending
img9313878_7.jpg Edgar Link pending
img9313878_8.jpg Edgar Link pending
img9313878_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending